International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 102609 Total View: 1666750
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Article http://dx.doi.org/10.26855/ijcemr.2023.04.004

A Case Report of Crohn’s Disease Combined with Psoriasis

Miao Xiang1, Sizhou Wang1, Mengjiao Zhang2, Heng Zhang2,*

1School of Medicine, Jianghan University, Wuhan, Hubei, China.

2Department of Gastroenterology, The Central Hospital of Wuhan, Wuhan, Hubei, China.

*Corresponding author: Heng Zhang

Published: May 25,2023

Abstract

Both Crohn's disease (CD) and psoriasis are autoimmune diseases whose pathogenesis is unclear. CD, together with Ulcerative colitis (UC), is called Inflammatory bowel disease (IBD), which is an abnormal immune response in individuals with genetic susceptibility to the stimulation of environmental factors and the joint participation of intestinal microorganisms, ultimately manifesting as an inflammatory response of the intestine. CD mainly presents as chronic inflammatory lesions of the gastrointestinal tract and often involves extraintestinal organs, including the skin, whereas psoriasis mainly presents as chronic inflammatory lesions of the skin. Here, we present a case of a 28-year-old man with a 1-year history of recurrent abdominal pain. He underwent intestinal CTE, colonoscopy, and histopathological evaluation, and in combination with the patient's past medical history, a diagnosis of CD with psoriasis was considered. In conclusion, CD with psoriasis is a relatively rare clinical case, and their relationship needs further studies to understand. Patients with CD combined with psoriasis have a high prevalence of anxiety and depressive symptoms, with up to one-third affected by anxiety symptoms and one-quarter by depressive symptoms, as well as an increased prevalence in patients with active disease.

References

[1] Inflammatory Bowel Disease Group of the Chinese Medical Association, Gastroenterology Branch. Consensus opinion on the diagnosis and treatment of inflammatory bowel disease (2018 - Beijing) [J]. Chinese Journal of Inflammatory Bowel Disease, 2018, 7(3): 173-190.

[2] Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23; 390(10114):2769-2778.

[3] Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij VJAA, van der Woude CJ, Vodegel RM, Fuhler GM, Peppelenbosch MP. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Oct; 23(10):1783-1789.

[4] Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Aug; 21(8):1982-92.

[5] Vide J, Osório F, Costa-Silva M, Lopes S, Azevedo F, Camila Dias C, Magina S, Magro F. Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study. J Crohns Colitis. 2018 Mar 28; 12(4):442-451. 

[6] Kim M, Choi KH, Hwang SW, Lee YB, Park HJ, Bae JM. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. J Am Acad Dermatol. 2017 Jan; 76(1):40-48.

[7] Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015 Jan-Feb; 90(1):9-20.

[8] Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017 Sep 7; 23(33):6137-6146. 

[9] Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with suscep-tibility to Crohn's disease. Nature. 2001 May 31; 411(6837):603-6. 

[10] Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Dec; 6(12):1002-1014. 

[11] Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018 Feb; 78(2):383-394. 

[12] Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021 May; 6(5):359-370. 

[13] Lamb CA. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec; 68(Suppl 3):s1-s106.

How to cite this paper

A Case Report of Crohn's Disease Combined with Psoriasis

How to cite this paper: Miao Xiang, Sizhou Wang, Mengjiao Zhang, Heng Zhang. (2023) A Case Report of Crohn's Disease Combined with Psoriasis. International Journal of Clinical and Experimental Medicine Research7(2), 121-127.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.04.004